USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies

USC PE-GCS：优化西班牙裔结直肠癌患者参与癌症基因组特征研究

基本信息

批准号：
10696237
负责人：
JOHN D. CARPTEN
金额：
$ 138.61万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-22 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10696237
关键词：
Address Advocate African American population Age Age Years Area Behavioral Behavioral Sciences Biology Biomedical Research California Cancer Etiology Cause of Death Cessation of life Characteristics Clinic Clinical Clinical Data Collaborations Colorectal Cancer Communication Communities Community Healthcare Community Outreach Consent Data Analyses Diagnosis Disease Ethnic Population Etiology Fasting Fostering Genome Genomics Goals Health Services Accessibility High Prevalence Hispanic Hispanic Populations Incidence Knowledge Laboratories Latino Latino Population Malignant Neoplasms Medical Mexican Molecular Not Hispanic or Latino Outcome Patient Preferences Patient-Focused Outcomes Patients Positioning Attribute Process Rectal Cancer Reporting Research Risk Scientist Subgroup Taxonomy Techniques Technology Testing The Cancer Genome Atlas Time Treatment Factor Underrepresented Minority Underserved Population cancer care cancer genome cancer genomics caucasian American clinical translation colon cancer patients community engagement demographics design early onset colorectal cancer genome sequencing genomic data health care settings improved member minority patient novel novel strategies participant enrollment patient engagement patient population research study socioeconomics translational cancer research translational genomics

项目摘要

ABSTRACT Colorectal Cancer (CRC) is the second leading cause of cancer death in the US. Hispanic/Latinos are the largest and fasting growing ethnic group in the US, and cancer is the leading cause of death among H/L in the US. Therefore, we need to fully understand the full complexity of the molecular etiology of cancer in this ethnic group. For instance, although incidence rates of CRC are lower among Latinos as compared to Whites or African Americans, Hispanics with metastatic disease have shorter overall survival when adjusted for health care setting, demographics, disease characteristics and treatment factors. H/L also tend to be diagnosed at a younger age and with higher stage, and we have previously reported that Mexican H/L in California have the greatest proportion of young (<50 years of age) diagnoses compared to other H/L subgroups. Moreover, Mexican H/L showed higher prevalence of rectal cancer cases compared to other H/L and NHW. Although socio-economics and access to care might influence these differences, we need to take a complete look at the biology of disease in this ethnic group to determine once and for all if these clinical differences are related to differences in molecular etiology. The Cancer Genome Atlas has provided a deep overview of the molecular taxonomy of CRC in 594 cases, however, less than 1% of the cases (n=5) were H/L. Therefore, it is imperative for us to take more detailed assessment of the molecular genomic landscape of CRC in H/L. One of the major issues likely limiting our ability to perform these large genomic initiatives in minority patients is that Patient or Participant Engagement practices may not been investigated to identify best practices for accruing and consenting patients into clinical translational biomedical research studies. This concept of Participant Engagement is critically important for both the patients and the translational cancer research community. Optimizing and improving our approaches for directly engaging patients at initial contact, throughout the course of a translational genomic study, and during the time of return of results is likely to lead to stronger relationships between the medical community and patients, but could also lead to significant improvement in outcomes for patients and for the cancer care community as a whole. As such, we propose the creation of the USC Center for Optimization of Participant Engagement in Cancer Characterization (COPECC) with a focus on optimizing the engagement of Latinos in CRC Genomic Characterization research studies. USC COPECC would serve as a member of the NCI U2C Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Our investigative team includes experts in all relevant areas of research for genomic characterization, participant engagement, and engagement optimization. We have an established platform for consenting patients into cancer genomics studies that will serve as a standard process. The overall goal of USC COPECC is to generate results on participant engagement optimization and CRC genomic research that will be shared with the broader community to distribute best practices for engaging Latinos in hopes of improving overall outcomes for CRC in this underserved population.

抽象的结直肠癌（CRC）是美国癌症死亡的第二大原因。西班牙裔/拉丁裔是最大的在美国禁食的族裔和癌症是美国H/L的主要原因。因此，我们需要充分了解这个族裔癌症分子病因的全部复杂性。例如，尽管与白人或非洲人相比，拉丁美洲人的CRC的发病率较低美国人，经过转移性疾病的西班牙裔人在调整医疗保健环境时的总体生存率较短，人口统计学，疾病特征和治疗因素。 H/L也倾向于在年轻时被诊断而且有更高的阶段，我们以前曾报道过，加利福尼亚州的墨西哥H/L。与其他H/L亚组相比，年轻人的诊断比例（<50岁）。此外，墨西哥H/L。与其他H/L和NHW相比，直肠癌病例的患病率更高。虽然社会经济学获得护理可能会影响这些差异，我们需要完整研究疾病的生物学在这个种族中，如果这些临床差异与分子的差异有关，则一劳永逸地确定病因。癌症基因组图集已经对594中CRC的分子分类法提供了深入的概述但是，案例不到1％的病例（n = 5）为H/L。因此，我们必须采取更详细的 H/L中CRC的分子基因组景观的评估。主要问题之一可能限制我们的能力在少数族裔患者中执行这些大型基因组倡议是患者或参与者参与习惯可能没有研究以确定将患者纳入临床翻译的最佳实践生物医学研究。参与者参与的概念对两个患者都至关重要以及转化癌症研究界。优化和改进我们直接的方法在翻译基因组研究的整个过程中，在初次接触时与患者互动结果的回报可能会导致医学界与患者之间的关系更强，但是还可能导致患者的结局和癌症护理界的结果显着改善所有的。因此，我们建议建立USC优化参与者参与中心癌症表征（COPECC），重点是优化拉丁裔在CRC基因组中的参与表征研究。 USC COPECC将担任NCI U2C参与者的成员参与和癌症基因组测序（PE-CGS）网络。我们的调查团队包括所有有关基因组表征，参与者参与和参与的研究领域优化。我们有一个已建立的平台，将患者同意参加癌症基因组学研究，这将用作标准过程。 USC COPECC的总体目标是为参与者参与产生结果优化和CRC基因组研究将与更广泛的社区共享，以分发最佳吸引拉丁美洲人的实践，希望在服务不足的人群中改善CRC的整体成果。